Skip to main content

Table 2 Reasons for discontinuation of treatment with bortezomib and dexamethasone (nā€‰=ā€‰40) and numbers of patients, which had conventional therapy in patients who discontinued bortezomib and dexamethasone with PD (nā€‰=ā€‰27)

From: Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

1) No. of patients who discontinued therapy n (%)

40 (100)

- CR with autologous stem cell transplantation

5 (12.5)

- CR without stem cell transplantation

1 (2.5)

- PD

27 (67.5)

- toxicity

1 (2.5)

- other reasons

6 (15.0)

2) No. of patients who had conventional chemotherapy in 27 patients who discontinued bortezomib and dexamethasone with PD n (%)

27 (100)

- conventional chemotherapy with autologous stem cell transplantation

6 (22.2)

- conventional chemotherapy with autologous stem cell transplantation and radiotherapy

1 (3.7)

- conventional chemotherapy with radiotherapy

1 (3.7)

- conventional chemotherapy alone

12 (44.4)

- no additional therapy

7 (25.9)

  1. CR: complete response; PD: progressive disease.